Literature DB >> 12654662

Use of genetically engineered phage to deliver antimicrobial agents to bacteria: an alternative therapy for treatment of bacterial infections.

Caroline Westwater1, Laura M Kasman, David A Schofield, Phillip A Werner, Joseph W Dolan, Michael G Schmidt, James S Norris.   

Abstract

The emergence and increasing prevalence of multidrug-resistant bacterial pathogens emphasizes the need for new and innovative antimicrobial strategies. Lytic phages, which kill their host following amplification and release of progeny phage into the environment, may offer an alternative strategy for combating bacterial infections. In this study, however, we describe the use of a nonlytic phage to specifically target and deliver DNA encoding bactericidal proteins to bacteria. To test the concept of using phage as a lethal-agent delivery vehicle, we used the M13 phagemid system and the addiction toxins Gef and ChpBK. Phage delivery of lethal-agent phagemids reduced target bacterial numbers by several orders of magnitude in vitro and in a bacteremic mouse model of infection. Given the powerful genetic engineering tools available and the present knowledge in phage biology, this technology may have potential use in antimicrobial therapies and DNA vaccine development.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12654662      PMCID: PMC152521          DOI: 10.1128/AAC.47.4.1301-1307.2003

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN: 0066-4804            Impact factor:   5.191


  43 in total

1.  Uptake and processing of modified bacteriophage M13 in mice: implications for phage display.

Authors:  Tom J M Molenaar; Ingrid Michon; Sonja A M de Haas; Theo J C van Berkel; Johan Kuiper; Erik A L Biessen
Journal:  Virology       Date:  2002-02-01       Impact factor: 3.616

2.  Topographic analysis of the toxic Gef protein from Escherichia coli.

Authors:  L K Poulsen; A Refn; S Molin; P Andersson
Journal:  Mol Microbiol       Date:  1991-07       Impact factor: 3.501

Review 3.  Antisense RNA-regulated programmed cell death.

Authors:  K Gerdes; A P Gultyaev; T Franch; K Pedersen; N D Mikkelsen
Journal:  Annu Rev Genet       Date:  1997       Impact factor: 16.830

Review 4.  Conditionally lethal genes associated with bacterial plasmids.

Authors:  Martin Holčík; V M Iyer
Journal:  Microbiology (Reading)       Date:  1997-11       Impact factor: 2.777

5.  Bacteriophage therapy rescues mice bacteremic from a clinical isolate of vancomycin-resistant Enterococcus faecium.

Authors:  Biswajit Biswas; Sankar Adhya; Paul Washart; Brian Paul; Andrei N Trostel; Bradford Powell; Richard Carlton; Carl R Merril
Journal:  Infect Immun       Date:  2002-01       Impact factor: 3.441

Review 6.  Programmed cell death in bacterial populations.

Authors:  M B Yarmolinsky
Journal:  Science       Date:  1995-02-10       Impact factor: 47.728

7.  Factor independent activation of rrnB P1. An "extended" promoter with an upstream element that dramatically increases promoter strength.

Authors:  L Rao; W Ross; J A Appleman; T Gaal; S Leirmo; P J Schlax; M T Record; R L Gourse
Journal:  J Mol Biol       Date:  1994-02-04       Impact factor: 5.469

8.  Evaluation of the biological containment system based on the Escherichia coli gef gene in Pseudomonas aeruginosa W51D.

Authors:  G Soberón-Chávez
Journal:  Appl Microbiol Biotechnol       Date:  1996-12       Impact factor: 4.813

9.  The Escherichia coli relBE genes belong to a new toxin-antitoxin gene family.

Authors:  M Gotfredsen; K Gerdes
Journal:  Mol Microbiol       Date:  1998-08       Impact factor: 3.501

10.  New killing system controlled by two genes located immediately upstream of the mukB gene in Escherichia coli.

Authors:  J Feng; K Yamanaka; H Niki; T Ogura; S Hiraga
Journal:  Mol Gen Genet       Date:  1994-04
View more
  55 in total

1.  Impact of relative humidity and collection media on mycobacteriophage D29 aerosol.

Authors:  Keyang Liu; Zhanbo Wen; Na Li; Wenhui Yang; Jie Wang; Lingfei Hu; Xiaokai Dong; Jianchun Lu; Jinsong Li
Journal:  Appl Environ Microbiol       Date:  2011-12-22       Impact factor: 4.792

2.  Engineered bacteriophage targeting gene networks as adjuvants for antibiotic therapy.

Authors:  Timothy K Lu; James J Collins
Journal:  Proc Natl Acad Sci U S A       Date:  2009-03-02       Impact factor: 11.205

3.  Competition in the presence of a virus in an aquatic system: an SIS model in the chemostat.

Authors:  Katherine Northcott; Mudassar Imran; Gail S K Wolkowicz
Journal:  J Math Biol       Date:  2011-06-14       Impact factor: 2.259

Review 4.  Enhancing the utility of existing antibiotics by targeting bacterial behaviour?

Authors:  Geraint B Rogers; Mary P Carroll; Kenneth D Bruce
Journal:  Br J Pharmacol       Date:  2012-02       Impact factor: 8.739

5.  Antibiotic adjuvants: diverse strategies for controlling drug-resistant pathogens.

Authors:  Erin E Gill; Octavio L Franco; Robert E W Hancock
Journal:  Chem Biol Drug Des       Date:  2015-01       Impact factor: 2.817

6.  Pharmacodynamics of non-replicating viruses, bacteriocins and lysins.

Authors:  James J Bull; Roland R Regoes
Journal:  Proc Biol Sci       Date:  2006-11-07       Impact factor: 5.349

Review 7.  Complementary and Alternative Medicine Strategies for Therapeutic Gut Microbiota Modulation in Inflammatory Bowel Disease and their Next-Generation Approaches.

Authors:  Abigail R Basson; Minh Lam; Fabio Cominelli
Journal:  Gastroenterol Clin North Am       Date:  2017-12       Impact factor: 3.806

8.  A tale of tails: Sialidase is key to success in a model of phage therapy against K1-capsulated Escherichia coli.

Authors:  J J Bull; E R Vimr; I J Molineux
Journal:  Virology       Date:  2009-12-16       Impact factor: 3.616

9.  Therapy of experimental pseudomonas infections with a nonreplicating genetically modified phage.

Authors:  Steven Hagens; André Habel; Uwe von Ahsen; Alexander von Gabain; Udo Bläsi
Journal:  Antimicrob Agents Chemother       Date:  2004-10       Impact factor: 5.191

10.  Bacteriophage-based synthetic biology for the study of infectious diseases.

Authors:  Robert J Citorik; Mark Mimee; Timothy K Lu
Journal:  Curr Opin Microbiol       Date:  2014-07-03       Impact factor: 7.934

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.